首页> 外文期刊>Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences >Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?
【24h】

Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?

机译:血清素受体1A-1019C / G变体:对忧郁症抑郁症的抗抑郁药物反应有影响吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies on the effects of serotonin receptor 1A (5-HT1A) gene variation on treatment response in depression revealed inconsistent results with studies pointing towards a detrimental influence of the 5-HT1A-1019G allele on antidepressant treatment response, while others did not discern any involvement of 5-HT1A variants. In order to further delineate the impact of 5-HT1A gene variation on pharmacoresponse in depression over 6 weeks of antidepressant treatment, the influence of the 5-HT1A-1019C/G (rs6295) polymorphism was investigated in 340 Caucasian patients with a Major Depressive Episode (DSM-IV) with particular attention to the subtype of depression (major depression and melancholic depression). Antidepressant treatment response across 5-HT1A-1019C/G genotype groups showed no differences in either Major Depressive Episode or major depression between genotype groups, whereas stratification for the melancholic subtype of depression revealed a significantly worse treatment response as conferred by the -1019CC genotype (p=0.02). The poorer treatment response in melancholic depression could first be detected in week 2 (p=0.03), continuing until week 6 and showing a maximum effect in week 3 (p=0.01). The present study adds to the clarification of the role of 5-HT1A variation in treatment response in major depression by providing preliminary support for poor treatment response mediated by the 5-HT1A-1019C allele repressing 5-HT1A activity specifically in the melancholic subtype of depression.
机译:先前有关5-羟色胺受体1A(5-HT1A)基因变异对抑郁症治疗反应影响的研究显示不一致的结果,研究指向5-HT1A-1019G等位基因对抗抑郁药治疗反应具有有害影响,而其他研究则没有发现5-HT1A变体的参与。为了进一步描述5-HT1A基因变异对抗抑郁药治疗6周以上抑郁症中药效学响应的影响,在340例高抑郁症白种人患者中研究了5-HT1A-1019C / G(rs6295)多态性的影响。 (DSM-IV),尤其要注意抑郁症的亚型(重度抑郁症和忧郁症抑郁症)。 5-HT1A-1019C / G基因型组的抗抑郁药治疗反应在基因型组之间的主要抑郁发作或主要抑郁症中均无差异,而对忧郁症亚型抑郁症的分层显示,治疗反应明显差于-1019CC基因型( p = 0.02)。忧郁症抑郁患者较差的治疗反应可能首先在第2周被发现(p = 0.03),一直持续到第6周并在第3周显示出最大的疗效(p = 0.01)。本研究通过为5-HT1A-1019C等位基因介导的5-HT1A活性抑制抑郁症的5-HT1A活性提供初步支持,从而进一步阐明5-HT1A变异在重度抑郁症治疗反应中的作用。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号